The current indication for tofacitibine citrate tablets is rheumatoid arthritis, which is temporarily not indicated for scleroderma, which can be treated with hormones and immunosuppressive agents.
Tofacitib citrate tablets are an oral protein tyrosine kinase inhibitor indicated for moderately to severely active rheumatoid arthritis in which methotrexate is not sufficiently efficacious or cannot tolerate methotrexate therapy. It is not currently approved for the treatment of scleroderma and its efficacy in scleroderma is unknown.
The drug may cause serious infections, gastrointestinal perforation and other adverse reactions. It is contraindicated in people who are allergic to the drug. Take care to prevent and treat infections during the use of the drug, and monitor for gastrointestinal bleeding. It is recommended to use the drug in accordance with the doctor’s instructions.
Scleroderma is a connective tissue disease, limited scleroderma treatment can be topical immunosuppressant, such as tacrolimus ointment; systemic scleroderma can use prednisone, methylprednisolone and other glucocorticosteroids and immunosuppressant such as methotrexate, cyclophosphamide. There are individual differences in the specific medication, and professional doctor’s guidance is required.
Patients are advised to go to the hospital in time to avoid delay.